We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Bladder Cancer Sniffed Out by Urine Tester

By LabMedica International staff writers
Posted on 22 Jul 2013
A device has been developed that can help diagnose the early stages of bladder cancer by analyzing the gas emitted from urine.

The device analyzes the chemicals in the urine odor or headspace and produces a profile readout that shows whether cancer cells are present in the bladder.

Scientists at the University of Liverpool (UK) fabricated a new simple in-house gas chromatography (GC)-sensor device and evaluated it in the diagnosis of bladder cancer based on volatiles. More...
A total of 98 male patients, aged 27 to 91 years, were recruited from urology clinics. There were 24 with bladder cancer and 74 controls, who were patients undergoing investigation for symptoms of bladder outflow obstruction and or hematuria.

The presence of specific volatile organic compounds (VOCs) in the gas emitted from urine samples was analyzed using the in-house fabricated sensor system, called the Odoreader. This consisted of the Clarus 500 gas chromatography oven (PerkinElmer; Waltham, MA, USA) fitted with a commercially available capillary column (Sigma Aldrich; Dorset, UK) which was interfaced to a metal oxide sensor heated to 450 °C that was used as the detector. Additional assistance in evaluating the device was provided by investigators from the University of the West of England (Bristol, UK).

Analysis of the chromatograms showed that 83.3% of bladder cancer samples had a measurable peak in a specific region. In the control samples, peaks in that region of the spectra were predominantly absent. Sensor outputs were analyzed using two different, independent data analysis techniques each of which showed significant discrimination of samples from patients with and without bladder cancer. The identity of the VOCs that contribute to the biomarker profile has yet to be determined. Their characterization may be defined in future work using gas chromatography mass spectrometry techniques and this will provide further insight into bladder cancer induced biochemical changes.

Christopher S. Probert, MD, a senior author of the study said, “Bladder cancer is a disease that, if caught early, can be treated effectively, but unfortunately we do not have any early screening methods other than diagnosis through urine tests at the stage when it starts to become a problem. We have developed a device that can give us a profile of the odor in urine. It reads the gases that chemicals in the urine can give off when the sample is heated.” The study was published on July 8, 2013, in the journal Public Library of Science ONE.

Related Links:

University of Liverpool
PerkinElmer
Sigma Aldrich



Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Gold Member
Latex Test
SLE-Latex Test
New
Francisella Tularensis Test
TULAREMIA VIRCLIA IgG+IgM MONOTEST
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: A biomarker discovery pipeline has shown promise as a noninvasive method of diagnosing CRC (Photo courtesy of NCI Center for Cancer Research)

Machine Learning Tool Enables Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States when considering both genders. Colonoscopy remains the gold standard for CRC diagnosis, but it is invasive,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.